Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-33038 Alaunos Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 84-1475642 (State or Other ...

ZIOPHARM Oncology, Inc. (ZIOP) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Kevin Boyle – CEO Alex Lobo – Chair Investor Relations Raffaele Baffa – Chief Medical Officer Conference Call Participants Emily Milligan – Cantor Fitzgerald Arthur Hey – H.C. Thomas Flaten – Lake Street Capital Markets Operator Greetings. Welcome to ZIOPHARM Oncology Third Quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer sess ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1475642 (State or other jurisdiction of incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33038 ZIOPHARM Oncology, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 84-14 ...

| --- | --- | |--------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | Vishay Precision Group PERFORMANCE THROUGH PRECISION VPG Second Fiscal Quarter 2021 Earnings — August 10, 2021 | | | PERFORMANCE THROUGH PRECISION | | Safe Harbor Statement From time to time, information provided by us, including but not limited to statements in this report, or other statements made by or on our behalf, may contain "forwardloo ...

ZIOPHARM Oncology, Inc. (ZIOP) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Adam Levy – Executive Vice President-Corporate Development and Investor Relations Heidi Hagen – Interim Chief Executive Officer Raffaele Baffa – Chief Medical Officer Ellee de Groot – Executive Vice President and General Manager-Cell Therapy Conference Call Participants Operator Greetings. Welcome to the Ziopharm Oncology, Inc. Second Quarter 2021 Corporate Update. At this time, all participants ar ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-----------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | \| @ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ...

ZIOPHARM Oncology, Inc. (ZIOP) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Adam Levy - Executive Vice President, Investor Relations and Corporate Communications Heidi Hagen - Interim Chief Executive Officer Raffaele Baffa - Chief Medical Officer James Huang - Executive Chairman Ellee de Groot - Executive Vice President and General Manager of Cell Therapy Conference Call Participants Chris Howerton - Jefferies David Novak - Raymond James Yale Jen - Laidlaw & Co Thomas Flaten ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-33038 ZIOPHARM Oncology, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorpo ...